These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34750652)

  • 1. Polyether ionophore kijimicin inhibits growth of Toxoplasma gondii and controls acute toxoplasmosis in mice.
    Leesombun A; Nihei CI; Kondoh D; Nishikawa Y
    Parasitol Res; 2022 Jan; 121(1):413-422. PubMed ID: 34750652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antibiotic monensin causes cell cycle disruption of Toxoplasma gondii mediated through the DNA repair enzyme TgMSH-1.
    Lavine MD; Arrizabalaga G
    Antimicrob Agents Chemother; 2011 Feb; 55(2):745-55. PubMed ID: 21098240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the polyether ionophorous antibiotic monensin against the cyst form of Toxoplasma gondii.
    Couzinet S; Dubremetz JF; Buzoni-Gatel D; Jeminet G; Prensier G
    Parasitology; 2000 Oct; 121 ( Pt 4)():359-65. PubMed ID: 11072898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress generated during monensin treatment contributes to altered Toxoplasma gondii mitochondrial function.
    Charvat RA; Arrizabalaga G
    Sci Rep; 2016 Mar; 6():22997. PubMed ID: 26976749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising
    Esboei BR; Keighobadi M; Hezarjaribi HZ; Fakhar M; Daryani A; Chabra A; Soosaraei M; Yalveh R
    Infect Disord Drug Targets; 2021; 21(1):151-155. PubMed ID: 32389115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro and In Vivo Activities of Tilmicosin and Acetylisovaleryltylosin Tartrate against
    Ma Y; Cao X; Wang H; Song X; Hu D
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076987
    [No Abstract]   [Full Text] [Related]  

  • 7. Transcriptional changes in Toxoplasma gondii in response to treatment with monensin.
    Zhai B; He JJ; Elsheikha HM; Li JX; Zhu XQ; Yang X
    Parasit Vectors; 2020 Feb; 13(1):84. PubMed ID: 32070423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance towards monensin is proposed to be acquired in a Toxoplasma gondii model by reduced invasion and egress activities, in addition to increased intracellular replication.
    Thabet A; Schmidt J; Baumann S; Honscha W; VON Bergen M; Daugschies A; Bangoura B
    Parasitology; 2018 Mar; 145(3):313-325. PubMed ID: 28870270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome Profiling of
    Harun MSR; Taylor M; Zhu XQ; Elsheikha HM
    Microorganisms; 2020 Jun; 8(6):. PubMed ID: 32512820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Heptaprenyl Diphosphate Synthase (Coq1) Is the Target of a Lipophilic Bisphosphonate That Protects Mice against Toxoplasma gondii Infection.
    Sleda MA; Li ZH; Behera R; Baierna B; Li C; Jumpathong J; Malwal SR; Kawamukai M; Oldfield E; Moreno SNJ
    mBio; 2022 Oct; 13(5):e0196622. PubMed ID: 36129297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New life for an old drug: In vitro and in vivo effects of the anthelmintic drug niclosamide against Toxoplasma gondii RH strain.
    Zhang JL; Si HF; Shang XF; Zhang XK; Li B; Zhou XZ; Zhang JY
    Int J Parasitol Drugs Drug Resist; 2019 Apr; 9():27-34. PubMed ID: 30599391
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Nishi L; Sanfelice RADS; da Silva Bortoleti BT; Tomiotto-Pellissier F; Silva TF; Evangelista FF; Lazarin-Bidóia D; Costa IN; Pavanelli WR; Conchon Costa I; Baptista ATA; Bergamasco R; Falavigna-Guilherme AL
    Parasitology; 2021 Oct; 148(12):1447-1457. PubMed ID: 34187608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NADPH Oxidase and Guanylate Binding Protein 5 Restrict Survival of Avirulent Type III Strains of Toxoplasma gondii in Naive Macrophages.
    Matta SK; Patten K; Wang Q; Kim BH; MacMicking JD; Sibley LD
    mBio; 2018 Aug; 9(4):. PubMed ID: 30154263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metacytofilin Is a Potent Therapeutic Drug Candidate for Toxoplasmosis.
    Leesombun A; Iijima M; Umeda K; Kondoh D; Pagmadulam B; Abdou AM; Suzuki Y; Ohba SI; Isshiki K; Kimura T; Kubota Y; Sawa R; Nihei CI; Nishikawa Y
    J Infect Dis; 2020 Feb; 221(5):766-774. PubMed ID: 31573038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells.
    Dzitko K; Grzybowski MM; Pawełczyk J; Dziadek B; Gatkowska J; Stączek P; Długońska H
    Parasit Vectors; 2015 Aug; 8():422. PubMed ID: 26272689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boromycin Has Potent Anti-
    Abenoja J; Cotto-Rosario A; O'Connor R
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468470
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted Phenotypic Screening in
    Subramanian G; Belekar MA; Shukla A; Tong JX; Sinha A; Chu TTT; Kulkarni AS; Preiser PR; Reddy DS; Tan KSW; Shanmugam D; Chandramohanadas R
    mSphere; 2018; 3(1):. PubMed ID: 29359192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two small-molecule inhibitors of
    Hua QQ; Lin XJ; Xiang SP; Jiang LY; Cai JH; Sun JM; Tan F; Mou YN
    Front Cell Infect Microbiol; 2023; 13():1145824. PubMed ID: 37077525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-parasitic activity of a chimeric peptide Cecropin A (2-8)-Melittin (6-9) (CM11) against tachyzoites of Toxoplasma gondii and the BALB/c mouse model of acute toxoplasmosis.
    Abbasali Z; Pirestani M; Dalimi A; Badri M; Fasihi-Ramandi M
    Mol Biochem Parasitol; 2023 Sep; 255():111578. PubMed ID: 37348706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain.
    Liu S; Wu M; Hua Q; Lu D; Tian Y; Yu H; Cheng L; Chen Y; Cao J; Hu X; Tan F
    Parasit Vectors; 2020 May; 13(1):242. PubMed ID: 32393321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.